For early-stage HER2-positive breast cancers who achieve a pCR to NAC, the NRG-BR008 (“HERO”) trial (Table 2) is a phase III randomized trial evaluating the omission of adjuvant radiotherapy. The gene discussed is ERBB2; the disease is breast cancer.